Financials Amniotics AB Deutsche Boerse AG
Equities
66J
SE0015961016
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 EUR | 0.00% | -50.00% | -50.00% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Capitalization 1 | 174.5 | 19.04 | 6.013 | 6.013 | - |
Enterprise Value (EV) 1 | 130.5 | 19.04 | 24.39 | -1.887 | 6.013 |
P/E ratio | -3.25 x | - | - | - | - |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | -3.38 x | -0.42 x | -0.91 x | -0.25 x | -0.25 x |
EV / FCF | -11,160,105 x | - | - | - | - |
FCF Yield | -0% | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 16,066 | 16,066 | 2,733,052 | 2,733,052 | - |
Reference price 2 | 10.86 | 1.185 | 0.002200 | 0.002200 | 0.002200 |
Announcement Date | 22-02-17 | 23-01-19 | 24-02-22 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net sales | 0.0376 | - | - | - | - | - |
EBITDA 1 | - | -51.62 | -44.9 | -26.77 | -23.7 | -23.6 |
EBIT 1 | - | -53.62 | -46.69 | -29.07 | -23.7 | -23.6 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -53.62 | -48.05 | -30.87 | -23.7 | -23.6 |
Net income 1 | -31 | -53.62 | -48.05 | -30.87 | -23.7 | -23.6 |
Net margin | -82,329.93% | - | - | - | - | - |
EPS | - | -3.340 | - | - | - | - |
Free Cash Flow | - | -15.63 | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 21-03-18 | 22-02-17 | 23-01-19 | 24-02-22 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | 44 | - | - | 7.9 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | -15.6 | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 21-03-18 | 22-02-17 | 23-01-19 | 24-02-22 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+42.92% | 58.06B | |
-5.69% | 40.53B | |
+37.52% | 38.99B | |
+14.19% | 26.7B | |
-12.56% | 26.56B | |
-21.71% | 18.98B | |
-0.38% | 12.17B | |
+23.74% | 12B | |
+24.99% | 11.92B |
- Stock Market
- Equities
- AMNI Stock
- 66J Stock
- Financials Amniotics AB